...
首页> 外文期刊>Human Pathology >Papillary urothelial neoplasm of low malignant potential of the urinary bladder: clinicopathologic and outcome analysis from a single academic center.
【24h】

Papillary urothelial neoplasm of low malignant potential of the urinary bladder: clinicopathologic and outcome analysis from a single academic center.

机译:膀胱恶性可能性低的乳头状尿路上皮肿瘤:来自单个学术中心的临床病理和结果分析。

获取原文
获取原文并翻译 | 示例
           

摘要

Few long-term single-center studies have addressed the outcome of patients with papillary urothelial neoplasms of low malignant potential. Our study evaluates the behavior of these tumors occurring as primary urinary bladder lesions. For this purpose, 34 primary in-house cases diagnosed and treated between 1998 and 2008 were identified from our medical records. Upon review, 3 cases were upgraded to noninvasive low-grade urothelial carcinomas and excluded from further evaluation. During follow-up (range, 3-108 months; mean, 42 months), 13 patients developed recurrences; and 9 patients progressed to a noninvasive higher grade lesion (8 to low-grade and 1 to high-grade urothelial carcinomas). None of our patients developed stage progression (>pTa) or died of bladder cancer. Size of the primary tumor was associated with the risk of recurrence (P = .043), whereas the number of episodes of recurrence was associated with the likelihood of grade progression (P = .034). In conclusion, recurrences were observed in 42% of all our patients, with a grade progression rate of 29%. None of our patients developed invasive carcinoma or died as a consequence of their disease. Considering the low but definitive risk of recurrence and grade progression, appropriate clinical follow-up of patients with primary papillary urothelial neoplasm of low malignant potential is warranted.
机译:很少有长期的单中心研究解决恶性程度低的乳头状尿路上皮肿瘤患者的预后。我们的研究评估了这些肿瘤作为原发性膀胱病变的行为。为此,从我们的病历中确定了1998年至2008年之间诊断和治疗的34例内部主要病例。经复查,有3例患者升级为无创性低度尿路上皮癌,被排除在进一步评估之外。随访期间(3-108个月;平均42个月),有13例患者复发。 9例患者进展为无创性更高级别的病变(8例归为低度,1例归为高级别的尿路上皮癌)。我们的患者均未出现阶段进展(> pTa)或死于膀胱癌。原发肿瘤的大小与复发风险相关(P = .043),而复发发作的次数与分级进展的可能性相关(P = .034)。总之,在我们所有患者中有42%观察到复发,分级进展率为29%。我们的患者均未出现浸润性癌或因疾病而死亡。考虑到复发和分级进展的风险较低但确定的风险,因此必须对恶性潜能低的原发性乳头尿路上皮肿瘤患者进行适当的临床随访。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号